Lakefront Biotherapeutics (GLPGF) Stock Price & Analysis
Lakefront Biotherapeutics (GLPGF) — price $31.95 (0.00%), as of the Oct 2, 2026 trading session; market cap $2.11B.
Educational signal · not a buy or sell recommendation · How to read this
Lakefront Biotherapeutics · GLPGF
Galapagos N.V. is an integrated biopharmaceutical company headquartered in Belgium, dedicated to discovering, developing, and commercializing innovative medicines for high unmet medical needs. The company maintains a robust pipeline of drug candidates targeting various inflammatory, fibrotic, and kidney diseases, supported by strategic collaborations with global pharmaceutical leaders.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $31.95 | |
| Change on the day | 0.00% | |
| 52-week range | $26.24 – $34.00 | |
| Market capitalisation | $2.11B | |
| Price / earnings (trailing) | 3.47 | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for Lakefront Biotherapeutics (GLPGF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the GLPGF film — every key number, told as a short cinematic story
~2 min · open the film
What is Lakefront Biotherapeutics (GLPGF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Lakefront Biotherapeutics (GLPGF) is the company analyzed here. It employs 452 people and is led by Henry Gosebruch. In Q2 FY2026 it reported revenue of $14M and net income of $2M. The market values it at $2.11B.
What do the latest results show for Lakefront Biotherapeutics (GLPGF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $14M. Against analyst estimates the company has EPS beat 4 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $14M | $2M | $0.03 (diluted) |
| Q1 FY2026 | $7M | $16M | $0.24 (diluted) |
| Q4 FY2025 | $1.01B | $878M | $13.32 (diluted) |
| Q3 FY2025 | $80M | -$227M | -$3.44 (diluted) |
What are the financial strengths and risks for Lakefront Biotherapeutics (GLPGF)?
Short answer
The distress and quality screens read Altman Z 14.47 · Piotroski F 4. Trailing ratios: ROE 16.9% · ROA 14.5% · current ratio 30.48 · earnings yield 28.7% · free-cash-flow yield -17.8%.
What has been published about Lakefront Biotherapeutics (GLPGF)?
Common Questions About GLPGF
These answers are editorial: 1 of these 8 answers is drawn from the GLPGF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is GLPGF a good stock to buy?
Stock Expert AI does not rate GLPGF buy, sell or hold. Lakefront Biotherapeutics has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the GLPGF stock price today?
The last price recorded on this page for Lakefront Biotherapeutics (GLPGF) is $31.95, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for GLPGF, particularly regarding its pipeline?
The primary risks for GLPGF are inherently tied to the high-risk nature of biopharmaceutical development. A significant concern is the potential for clinical trial failures, where drug candidates may not demonstrate sufficient efficacy or safety, leading to program termination and substantial financial losses.
What are the key factors to evaluate for GLPGF?
Evaluate GLPGF on fundamentals, analyst consensus, and risk factors. P/E: 3.47x. Galapagos N.V. has established strategic collaboration agreements with major pharmaceutical companies including Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG, enhancing its development capabilities and market reach. Not financial advice.
How frequently does GLPGF data refresh on this page?
GLPGF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven GLPGF's recent stock price performance?
Lakefront Biotherapeutics (GLPGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse and active clinical pipeline targeting multiple high unmet medical needs across inflammatory, fibrotic, and kidney diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GLPGF overvalued or undervalued right now?
Lakefront Biotherapeutics (GLPGF) trades at 3.47x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GLPGF before investing?
Before investing in Lakefront Biotherapeutics (GLPGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (15 figures)
The 15 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $31.95 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T10:45:02.015Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $2.11B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T10:45:01.008Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 3.47 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 100 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $14M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $2M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $26.24 – $34.00 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.employees | Employees | 452 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.ceo | Chief executive | Henry Gosebruch | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-30 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 14.47 · Piotroski F 4 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 16.9% · ROA 14.5% · current ratio 30.48 · earnings yield 28.7% · free-cash-flow yield -17.8% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.